Oxford Biomedica and VMIC seal UK vaccine manufacturing capacity deal
The collaboration will significantly increase the UK’s capacity to manufacture viral vectors vaccines as part of a national effort in response to COVID-19.
Cell and gene therapy-focused CDMO Oxford Biomedica has signed a five-year collaboration agreement with the Vaccines Manufacturing and Innovation Centre (VMIC) for the manufacture of viral vector based vaccines, including AstraZeneca’s adenovirus vector based COVID-19 vaccine candidate, AZD1222.
Under the terms of the agreement, VMIC will provide manufacturing equipment for Oxford Biomedica to equip two new GMP manufacturing suites within Oxford Biomedica’s new 7,800 m2 commercial manufacturing centre, Oxbox, located in Oxford, UK.
This will provide significant additional manufacturing capacity and enable further scale-up for AZD1222 from the summer of 2020, as needed, to help supply UK and European vaccine demand. These suites could also be used for other viral vector vaccine candidates.
Oxford Biomedica will provide training and technical assistance to VMIC staff to accelerate the operational readiness and GMP manufacturing capabilities for viral vector vaccine candidates at VMIC’s new manufacturing site located at the Harwell Science and Innovation Campus, due to open in mid-2021, a year ahead of schedule.
The agreement also provides a framework for a longer-term partnership between Oxford Biomedica and VMIC, whereby Oxford Biomedica could rapidly provide its commercial-scale manufacturing capacity to supply other novel viral vector vaccine candidates for the UK population, when needed.
Viral vector COVID-19 vaccine candidates are showing promise. According to Kate Bingham, Chair of the UK Vaccine Taskforce, this new partnership between VMIC and Oxford Biomedica “will specifically help ensure that we have the right skills in place to manufacture a vaccine as soon as one is available”.
VMIC and Oxford Biomedica are original members of the Oxford University manufacturing consortium focussed on scaling-up the GMP manufacture of AZD1222, which has entered clinical trials at multiple sites in the UK.
AstraZeneca has now taken over global responsibility for the manufacturing, development and distribution for AZD1222 with an initial clinical and commercial supply agreement for multiple batches.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance